Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,510.50
Bid: 1,511.00
Ask: 1,511.50
Change: 7.00 (0.47%)
Spread: 0.50 (0.033%)
Open: 1,514.00
High: 1,518.50
Low: 1,507.50
Prev. Close: 1,503.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Messy markets! What to buy?

Wed, 21st Oct 2020 12:28

* European stocks fall for second straight session

* Centamin shares down 20% after production update

* Construction sector dips 1.5%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

MESSY MARKETS! WHAT TO BUY? (1128 GMT)

A vaccine approval, shorter/less-strict social restrictions, coupled with a strong economic
growth, a moderate rise in inflation rates and a weak dollar are possibilities to look forward
to in 2021.

And, if this materializes, Credit Suisse analysts have some ideas:

- European renewables, as wind capacity is expected to rise by 15-fold in the next 20 years
and the carbon price to be at $100 ton by 2030; besides grids deserve un upgrade, including RWE
, EDP,, National Grid

- Mining stocks, thanks to Chinese infrastructure investments seen remaining strong. CS
analysts highlight Anglo American.

- Construction materials, as U.S. housing is set to grow 20% on very low bond yields and
governments are focused on infrastructure. They “like stocks exposed to insulation.”

- China tech, as P/E relatives are at 15-year lows while earnings revisions remain very
strong and there are “all the ingredients of a bubble that has yet to really start.”

- Defence, as spending will grow in a tri-polar world and telecom equipment with 5G a
superfast broadband seen as a necessity. CS says U.S. valuations in defence sector at 20-year
lows, with BAE “looking abnormally cheap.”

(Stefano Rebaudo)

*****

WHEN WILL UK DIVIDENDS BOUNCE BACK TO PRE-PANDEMIC LEVELS? (0900 GMT)

It's anyone's guess!

Link Group says the best case scenario is a recovery to 2012-13 levels in 2021.

UK dividends have recovered a tad from the depths of last quarter but they still had the
lowest third quarter in ten years, leaving investors eager to find out how much they will wait
to see payouts levels bouncing back.

Underlying dividends, which exclude special payments, fell 45.1% to £17.7bn in Q3, according
to Link Group.

"Though by any normal standards a fall of this magnitude is terrible for investors, it is
significantly better than the 57.2% drop in the second quarter," it says.

Link Group adds that investors will likely only see dividends recovering by March 2021 and
it pencils in a best-case increase of 15% and a worst case of 6% for next year.

"The fourth quarter this year and the first quarter next are set for further sharp declines,
but from April onwards, the anniversary of the lockdown, the comparisons will start to look more
favourable and we expect to see a bounce-back begin".

(Joice Alves)

******

EUROPEAN STOCKS HEAD LOWER (0800 GMT)

European stocks dipped for the second straight day dragged down by construction, healthcare
and oil outweighing a decent batch of better-than-expected Q3 results.

The STOXX 600 is down 0.6%, with the construction sector leading the losses.

In terms of single stocks, Shares in Ericsson are up 7%, after quarterly core
earnings beat market estimates and the company says it is "more confident" in meeting its 2020
targets.

Mining company Centamin's shares fell to the bottom of the pan European index, down
18% after the company’s production update.

Shares in Iberdrola are down 0.6%, after the company issued results and announced
its U.S. unit Avangrid agreed to buy U.S. utility PNM Resources for around $4.3
billion.

(Stefano Rebaudo and Joice Alves)

*****

ON THE RADAR: IBERDROLA UNIT MERGER, AKZO NOBEL, ERICSSON (0639 GMT)

European stocks are poised to open higher, with sentiment boosted by hopes for a U.S. rescue
package and better-than-feared earnings results.

While concerns about the pandemic in Europe continue to weigh, we have a decent batch of
corporate news to cheer up investors, starting with a multi-billion cross border merger in the
renewable energy sector. Avangrid, the U.S. unit of Iberdrola, has agreed to
buy U.S. utility PNM Resources for around $4.3 billion. The merged company would have
assets worth $40 billion and generate core earnings of around $2.5 billion and net profit of
$850 million.

Akzo Nobel reports a better-than-expected 18% increase in third-quarter core
profit to 353 million euros.

Nestle stocks are up 2.7% in premarket trade after the company beats Q3 sales
expectations and raises its guidance for 2020.

Ericsson quarterly core earnings beat market estimates, helped by higher margins
and China's 5G rollout, and is "more confident" in meeting its 2020 targets.

Good news also on the vaccine front as AstraZeneca Plc's trial in the United States
is expected to resume as early as this week after the U.S. Food and Drug Administration
completed its review of a serious illness in a study participant.

But we still see pressure on the financial sector. Shares in GAM Holding are down
2.2% in premarket trade after results., while Handelsbanken reports
lower-than-expected quarterly net earnings due to restructuring costs.

Vinci expects earnings to continue falling in the second half of the year, as
weakness at its pandemic-ravaged airports business outweighs signs of a recovery in construction
and motorway traffic.

GlaxoSmithKline would move its experimental vaccine against the respiratory
syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of
testing, encouraged by mid-stage trial results.

Shares in Bilfinger are up 7.2% after press reports on possible takeover of the
company.

(Stefano Rebaudo)

*****

EUROPE CAUTIOUSLY IN THE BLACK (0528 GMT)

European stock futures are in the black along with their U.S. peers as hopes of a quick
approval of a U.S. stimulus package are propping up risk sentiment.

But investors continue to be cautious as coronavirus trajectories as well as possible new
restrictive measures are now seen as the single biggest near-term risk to the economic recovery.

Italy, Spain and Britain are considering new restrictions, including curfew in hard-hit
regions, to limit the spread of the pandemic. The latest curbs in Ireland will see GDP fall by
3.5% this year, Finance Minister Paschal Donohoe said.

(Stefano Rebaudo)

*****

More News
3 Oct 2023 18:19

IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer

GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.